Insilico Medicine
Generative AI drug discovery company (HKEX: 3696) operating both as a platform vendor and a clinical stage biotech. Pharma.AI comprises PandaOmics (AI target identification and indication prioritization), Chemistry42 (generative molecular design using generative tensorial reinforcement learning rather than library screening), and inClinico (clinical trial outcome prediction). The platform's flagship validation is rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis where AI selected the target, generated the molecule, and informed trial design: it entered a 320 patient Phase III trial in July 2026, with discovery published in Nature Biotechnology and Phase IIa results in Nature Medicine. The vendor reports reaching preclinical candidate nomination in 12 to 18 months on average against a 2.5 to 4 year industry norm, and 13 programs cleared for IND.
Capability Axes
AI is the mechanism end to end and is the company's actual claim to novelty: PandaOmics prioritized the target, Chemistry42 generated the molecule using generative tensorial reinforcement learning rather than screening existing libraries, and inClinico informed trial design. Rentosertib is the proof: a drug whose target, structure, and development were each AI driven.
Unusually specific for this index: named engines with disclosed methods (generative tensorial reinforcement learning in Chemistry42), and medicinal chemistry disclosed in peer reviewed literature. Held back from A because no model cards or technical documentation for the platform modules themselves were retrieved.
Pipeline progress is the evidence that matters in this category, and it is peer reviewed. Rentosertib discovery was published in Nature Biotechnology and Phase IIa results in Nature Medicine (reported mean FVC change of +98.4 mL at 12 weeks in the 60 mg arm against -20.3 mL for placebo), and the program entered a 320 patient Phase III in July 2026. Thirteen programs have reached IND clearance. Platform speed claims (12 to 18 months to preclinical candidate, 60 to 200 molecules synthesized per program) remain vendor reported.
Positioning is careful and correct. Rentosertib holds FDA Orphan Drug designation for IPF (2023) and was included in China's CDE Breakthrough Therapy list (2025), and both the company and coverage state plainly that it remains investigational and is not approved by any regulatory authority. No overclaiming.
No public pricing. Contact the vendor. The commercial surface is partnership and licensing structure rather than a platform rate card, which is the norm in drug discovery AI.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Pharma partnerships, licensing, and milestone structures; internal pipeline development | — | — | Vendor Published |
The commercial surface in drug discovery AI is partnership and licensing structure rather than a platform rate card. Insilico operates both as a platform vendor and as a clinical stage biotech developing its own assets, so economics vary by deal.